Extrahepatic manifestations of chronic hepatitis C virus infection

被引:206
作者
Cacoub, Patrice [1 ,2 ,3 ,4 ,5 ]
Gragnani, Laura [6 ]
Comarmond, Cloe [1 ,2 ,3 ,4 ,5 ]
Zignego, Anna Linda [6 ]
机构
[1] Univ Paris 06, Sorbonne Univ, UMR 7211, Paris, France
[2] Univ Paris 06, Sorbonne Univ, Inflammat Immunopathol Biotherapy Dept DHU i2B, Paris, France
[3] INSERM, UMR S 959, Paris, France
[4] CNRS, FRE3632, Paris, France
[5] Grp Hosp Pitie Salpetriere, AP HP, Dept Internal Med & Clin Immunol, F-75634 Paris, France
[6] Univ Florence, Dept Expt & Clin Med, Interdept Ctr Syst Manifestat Hepatitis Viruses M, Florence, Italy
关键词
Extra hepatic manifestations; HCV; Treatment; QUALITY-OF-LIFE; NON-HODGKINS-LYMPHOMA; MIXED CRYOGLOBULINEMIA VASCULITIS; MONOCLONAL-ANTIBODY TREATMENT; RANDOMIZED CONTROLLED-TRIAL; PEGYLATED INTERFERON-ALPHA; CHRONIC HCV INFECTION; B-CELL; ANTIVIRAL TREATMENT; INSULIN-RESISTANCE;
D O I
10.1016/j.dld.2014.10.005
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Hepatitis C virus (HCV) infected patients are known to be at risk of developing liver complications i.e. cirrhosis and liver cancer. However, the risks of morbidity and mortality are underestimated because they do not take into account non-liver consequences of chronic hepatitis C virus infection. Numerous extrahepatic manifestations have been reported in up to 74% of patients, from perceived to disabling conditions. The majority of data concern hepatitis C virus-related autoimmune and/or lymphoproliferative disorders, from mixed cryoglobulinaemia vasculitis to frank lymphomas. More recently, other hepatitis C virus-associated disorders have been reported including cardiovascular, renal, metabolic, and central nervous system diseases. This review aims to outline most of the extrahepatic manifestations that are currently being investigated, including some of autoimmune and/or lymphoproliferative nature, and others in which the role of immune mechanisms appears less clear. Beyond the liver, hepatitis C virus chronic infection should be analyzed as a multifaceted systemic disease leading to heavy direct and indirect costs. The accurate consideration of extrahepatic consequences of such a systemic infection significantly increases the weight of its pathological burden. The need for effective viral eradication measures is underlined. (C) 2014 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:S165 / S173
页数:9
相关论文
共 184 条
[1]   Chronic hepatitis C virus infection and atherosclerosis: Clinical impact and mechanisms [J].
Adinolfi, Luigi E. ;
Zampino, Rosa ;
Restivo, Luciano ;
Lonardo, Amedeo ;
Guerrera, Barbara ;
Marrone, Aldo ;
Nascimbeni, Fabio ;
Florio, Anna ;
Loria, Paola .
WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (13) :3410-3417
[2]   Chronic HCV infection is a risk of atherosclerosis. Role of HCV and HCV-related steatosis [J].
Adinolfi, Luigi E. ;
Restivo, Luciano ;
Zampino, Rosa ;
Guerrera, Barbara ;
Lonardo, Amedeo ;
Ruggiero, Laura ;
Riello, Francesco ;
Loria, Paola ;
Florio, Anna .
ATHEROSCLEROSIS, 2012, 221 (02) :496-502
[3]   Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C [J].
Aghemo, Alessio ;
Prati, Gian Maria ;
Rumi, Maria Grazia ;
Soffredini, Roberta ;
D'Ambrosio, Roberta ;
Orsi, Emanuela ;
De Nicola, Stella ;
Degasperi, Elisabetta ;
Grancini, Valeria ;
Colombo, Massimo .
HEPATOLOGY, 2012, 56 (05) :1681-1687
[4]   EVIDENCE FOR A LINK BETWEEN HEPATITIS-C VIRUS-INFECTION AND DIABETES-MELLITUS IN A CIRRHOTIC POPULATION [J].
ALLISON, MED ;
WREGHITT, T ;
PALMER, CR ;
ALEXANDER, GJM .
JOURNAL OF HEPATOLOGY, 1994, 21 (06) :1135-1139
[5]  
Ando H, 1998, DIABETIC MED, V15, P797, DOI 10.1002/(SICI)1096-9136(199809)15:9<797::AID-DIA675>3.0.CO
[6]  
2-M
[7]   Prevalence of monoclonal gammopathies in patients with hepatitis C virus infection [J].
Andreone, P ;
Zignego, AL ;
Cursaro, C ;
Gramenzi, A ;
Gherlinzoni, F ;
Fiorino, S ;
Giannini, C ;
Boni, P ;
Sabattini, E ;
Pileri, S ;
Tura, S ;
Bernardi, M .
ANNALS OF INTERNAL MEDICINE, 1998, 129 (04) :294-298
[8]  
[Anonymous], 2008, Kidney Int Suppl, V109, pS1
[9]   Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi [J].
Arcaini, L. ;
Vallisa, D. ;
Rattotti, S. ;
Ferretti, V. V. ;
Ferreri, A. J. M. ;
Bernuzzi, P. ;
Merli, M. ;
Varettoni, M. ;
Chiappella, A. ;
Ambrosetti, A. ;
Tucci, A. ;
Rusconi, C. ;
Visco, C. ;
Spina, M. ;
Cabras, G. ;
Luminari, S. ;
Tucci, M. ;
Musto, P. ;
Ladetto, M. ;
Merli, F. ;
Stelitano, C. ;
d'Arco, A. ;
Rigacci, L. ;
Levis, A. ;
Rossi, D. ;
Spedini, P. ;
Mancuso, S. ;
Marino, D. ;
Bruno, R. ;
Baldini, L. ;
Pulsoni, A. .
ANNALS OF ONCOLOGY, 2014, 25 (07) :1404-1410
[10]   Hepatitis C and carotid atherosclerosis: A retrospective analysis [J].
Aslam, Fawad ;
Alam, Mahboob ;
Lakkis, Nasser M. .
ATHEROSCLEROSIS, 2010, 209 (02) :340-343